IASIS PHARMA is pleased to announce the release of its new product ETROZAC®.
ETROZAC® active substance is etoricoxib which is a selective cox-2 inhibitor.
ETROZAC® is indicated for the relief of the symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis and the pain and symptoms of inflammation associated with Acute Gout. ETROZAC® is indicated for the short-term treatment of moderate pain associated with dental surgery.
ETROZAC® is available in packages of 14 or 20 film-coated tablets, in a wide dosage range:
Etrozac® 20 tabs x 60 mg
Etrozac® 14 tabs x 90 mg
Etrozac® 20 tabs x 90 mg
Etrozac® 20 tabs x 120 mg